Literature DB >> 9351562

Family history facilitates the early diagnosis of prostate carcinoma.

P C Walsh1, A W Partin.   

Abstract

BACKGROUND: Although all men age >50 years are at an increased risk for the development of prostate carcinoma, 2 major factors increase this risk: family history and race. This article outlines the influence of family history on the risk of prostate carcinoma and current understanding of factors that increase this risk.
METHODS: Published studies investigating the familial and hereditary link to prostate carcinoma are reviewed. The results of an investigation into the mendelian inheritance of prostate carcinoma are discussed as well as the relation between hereditary cancer syndromes such as breast and ovarian carcinoma and prostate carcinoma.
RESULTS: A positive family history of prostate carcinoma increases the relative risk of prostate carcinoma in male first-degree relatives approximately twofold. Prostate carcinoma is inherited as an autosomal dominant trait. The relative risk of prostate carcinoma increases with multiple affected relatives.
CONCLUSIONS: Hereditary prostate carcinoma is estimated to be associated with 43% of men in whom the diagnosis of prostate carcinoma is made at age <55 years, 34% of men in whom the diagnosis is made at age <70 years, and only 9% of men diagnosed before age 85 years. Hereditary prostate carcinoma should be suspected in families with an early age at onset of the disease and/or multiple affected family members. Because hereditary prostate carcinoma is characterized by an early age at onset, first-degree relatives in high risk families should begin screening before age 50 years.

Entities:  

Mesh:

Year:  1997        PMID: 9351562     DOI: 10.1002/(sici)1097-0142(19971101)80:9<1871::aid-cncr28>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population.

Authors:  Zorana Z Nikolić; Goran N Brajušković; Dušanka Lj Savić Pavićević; Aleksandar S Kojić; Vinka D Vukotić; Saša M Tomović; Snežana J Cerović; Vladimir Filipović; Duro Mišljenović; Stanka P Romac
Journal:  Int J Clin Exp Med       Date:  2012-11-18

3.  Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Authors:  Brian T Helfand; Haitao Chen; Richard J Fantus; Carly A Conran; Charles B Brendler; Siquan Lilly Zheng; Patrick C Walsh; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2018-06-19       Impact factor: 4.104

Review 4.  Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans.

Authors:  K Hemminki; C Eng
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

5.  Perceived risk and worry about prostate cancer: a proposed conceptual model.

Authors:  Julie B Schnur; Terry A DiLorenzo; Guy H Montgomery; Joel Erblich; Gary Winkel; Simon J Hall; Dana H Bovbjerg
Journal:  Behav Med       Date:  2006       Impact factor: 3.104

Review 6.  Genetic susceptibility to prostate cancer: a review.

Authors:  Bas A J Verhage; Lambertus A L M Kiemeney
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 7.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

8.  Familial risk of urological cancers: data for clinical counseling.

Authors:  Kari Hemminki; Xinjun Li; Kamila Czene
Journal:  World J Urol       Date:  2003-11-13       Impact factor: 4.226

Review 9.  Inherited predisposition to prostate cancer.

Authors:  Bas A J Verhage; Lambertus A L M Kiemeney
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  MCMDA: Matrix completion for MiRNA-disease association prediction.

Authors:  Jian-Qiang Li; Zhi-Hao Rong; Xing Chen; Gui-Ying Yan; Zhu-Hong You
Journal:  Oncotarget       Date:  2017-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.